Ghrelin growth hormone secretagogue receptor, with the "GHS-R1b" splice being inactive) is involved in mediating a wide variety of biological effects of ghrelin, including: stimulation of growth hormone release, increase in hunger, modulation of glucose and lipid metabolism, regulation of gastrointestinal motility and secretion, protection of neuronal and cardiovascular cells, and regulation of immune function. They are present in high density in the hypothalamus and pituitary, on the vagus nerve (on both afferent cell bodies and afferent nerve endings) and throughout the gastrointestinal tract. Ghrelin promotes intestinal cell proliferation and inhibits apoptosis during inflammatory states and oxidative stress. It also suppresses
Growth hormone in sports which the anterior pituitary gland produces excess growth hormone. Human growth hormone occurs naturally in the human body. Use of exogenous human growth hormone (HGH), via injection, was originally for medical purposes until athletes began abusing HGH with the goal of increasing their abilities. Before recombinant human growth hormone (rHGH) was developed in 1981, HGH was only available from cadavers. The arrival of rHGH combined with other peptide hormone advancements has increased the availability of HGH on both the legitimate and black markets. The first description of the use of GM as a doping agent was Dan Duchaine’s “Underground Steroid